This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mahadevan D, List AF . Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004; 104: 1940–1951.
Steinbach D, Legrand O . ABC transporters and drug resistance in leukemia: was Pgp nothing but the first head of the Hydra? Leukemia 2007; 21: 1172–1176.
Allen SL, Kolitz JE, Lundberg AS, Capizzi RL, Budman DR . Clinical and cytogenetic responses to amonafide in secondary acute myeloid leukemia (AML). J Clin Oncol 2006; 24: 6584 (abstract).
Erba HP, Rizzieri DA, O'Donnell MR, Lundberg AS, Ajami AM, Rampersad AD et al. Amonafide and ara-C treatment for secondary acute myeloid leukemia (sAML). J Clin Oncol 2007; 25: 7065 (abstract).
Chau M, Christensen JL, Ajami AM, Capizzi RL . Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leuk Res 2008; 32: 465–473.
Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Greco WR, Ross DD et al. Breast cancer resistance protein in acute myeloid leukemia: discordance between expression and function. Leukemia 2004; 18: 1252–1257.
Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 2005; 11: 2320–2326.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Burcu, M., O'Loughlin, K., Ford, L. et al. Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia 22, 2110–2115 (2008). https://doi.org/10.1038/leu.2008.87
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.87